 Supernus Pharmaceuticals Inc NASDAQ: SUPN recently announced that it had entered a definitive contract to acquire Adamas Pharmaceuticals NASDAQ: ADMS. Supernus is to purchase this company a tender offer that was worth about 8.10 per share. 